AVPR2 and autosomal dominant polycystic kidney disease: Currently, the vasopressin V2 receptor antagonist tolvaptan is the only approved drug for ADPKD treatment, but it is only suitable or approved for subsets of patients and has side effects like polyuria and liver toxicity.26